RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
#Offlabel use leads to a slow down of new #coronavirus #covid19 #drugs & #vaccines partly recommended by "Doctor" @realDonaldTrump Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/MR6dGUyYQM https://t.
RT @drjordirello: Avoid compasioned use: follow evidences and orrform RCT https://t.co/hAqSVdgzFl
@ThierryNutti @Drmartyufml Lisez plutôt ça et vous constaterez que Perronne Raoult et consors ne font que retarder les connaissance avec leurs utilisations sauvages ne permettant aucune conclusion valide. https://t.co/38NwMnbEV7
RT @DanielRodMD: Una Falacia Post hoc es la que pretende establecer una conclusión apelando a una falsa relación entre dos fenómenos. 👇🏻👇🏻…
*when a drug with unknown clinical effects is given to patients who have severe illness from a new disease (like COVID-19),there is no way to know whether the patients had benefited or were harmed if they were not #compared to a #concurrent #controlgroup *
*there are published case reports of old and new drugs with in vitro activity against SARS-CoV-2 that have been given to patients but without a comparison control group. * https://t.co/LLOLWUggNf
*Although many drugs have in vitro activity against different coronaviruses, #no #clinical #evidence currently supports the #efficacy and #safety of #any #drug against any #coronavirus in #humans , #including #SARS-CoV-2. * https://t.co/LLOLWUggNf
*These therapies have been mostly given #without #controls, except for a #few #randomized #trials started in #China, and more recently in the #US. * https://t.co/LLOLWUggNf
* convalescent plasma, steroids, and anti–IL-6 inhibitors, based on either their in vitro antiviral or anti-inflammatory properties. * https://t.co/LLOLWUggNf
*In China,...Italy, France, & Spain, a large number of patients have received off-label & #compassionateuse therapies such as chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, favipiravir, remdesivir, ribavirin, interferon, * http
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/LLOLWUggNf
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
Una Falacia Post hoc es la que pretende establecer una conclusión apelando a una falsa relación entre dos fenómenos. 👇🏻👇🏻 https://t.co/QgumIR15T6
Ce que je dis mais en mieux !!
@AbaziouTim https://t.co/38NwMnbEV7 tout l'argumentaire est bien detaillé là dedans...
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
“A common interpretation of off-label use and compassionate use of drugs is that is that if the patient died, they died from the disease, but if the patient survived, they survived because of the given drug. This is not true.” https://t.co/XF0uvy5jqC
Treating COVID-19-Off-Label and Compassionate Use and Clinical Trials During Pandemics - The JAMA Network https://t.co/jYYwFhwxUB via @nuzzel
RT @BldCancerDoc: "The rapid and simultaneous combination of supportive care and RCTs is the only way to find effective and safe treatments…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/vewE1YkG83
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
RT @MSharifpourMD: This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I rec…
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/yFYEMLE77z
This is a brilliant piece that was recently published in @JAMA_current about Off-Label and Compassionate drug use. I recommend it to any/everyone who treats patients with COVID19. And plz do not look at it with a political lens https://t.co/WPMmfBY3pW
RT @dr_alexandrap: Patients, families and health professionals are anxious during COVID19 please consider harm vs benefit and enrolling in…
RT @dr_alexandrap: Patients, families and health professionals are anxious during COVID19 please consider harm vs benefit and enrolling in…
Patients, families and health professionals are anxious during COVID19 please consider harm vs benefit and enrolling in randomized controlled trials; GeriMedRisk excellent resource
RT @GeriMedRisk: Please consider harmful drug-drug interactions and adverse drug effects with off-label COVID therapies. https://t.co/0Mpcw…
@NeilFlochMD Sorry but count me a sceptic. I've followed the immunomodulation for sepsis literature for two decades & am fearful that this uncritical enthusiasm will do its cause more harm than good. It was tried without success for Ebola https://t.co/
@HPJournalClub A5: need more of this. #HPJC
RT @rohankhaz: @HPJournalClub A3 #HPJC Not a legislative change, but @UNMC_ID is currently running an NIH-sponsored “adaptive” RCT, because…
RT @rohankhaz: @HPJournalClub A3 #HPJC Not a legislative change, but @UNMC_ID is currently running an NIH-sponsored “adaptive” RCT, because…
@HPJournalClub A3 #HPJC Not a legislative change, but @UNMC_ID is currently running an NIH-sponsored “adaptive” RCT, because rapidly moving through potential treatment options might help prevent adverse events from compassionate use drugs that have harmful
Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/EeKSWNnIOu
Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/nrhjLM1JkM
@matt622h @RebeccaGagne @marklewismd Here’s some good information on why believing this has anything to do with politics is just another form of bias. “Just doing something” is a human desire, but it’s a cognitive bias. https://t.co/NGWo2AfDdc
@drjohnm @DanMarkMD @GLamasMD @CMichaelGibson @PulmCrit @venkmurthy @hmkyale @skathire @ADAlthousePhD @statsepi how do you reconcile (1) and (2)? https://t.co/DICxbBwJLv
@kidney_boy IMHO, I think we should review what means to have a therapy. https://t.co/nVqUOZHlAS https://t.co/R6uAUuMwOC P. S. - am I the only one with ethical doubts about the "compassionate use" concept? namely the true meaning of "compassion". https:
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/fetwVB43Z7
Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/biClWUgS8g
@jenheemstra The waste of trials without controls is expressed eloquently here🔽. https://t.co/PAw1f7Te3y
RT @Saudi_Pharma_07: Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/ciArECR3EE
@DrToddLee @AnilMakam that would be a more apt term, but "compassionate use" is actually being used properly here https://t.co/LE9Y3HLgw9 of course compassionate use is an especially problematic idea in this setting: https://t.co/ZNYxwh66me
read andre kalil on why "compassionate use" seems like a good idea but isn't https://t.co/LoF4efhkHc
RT @GermHunterMD: @nikkitheomd But this is under the generous assumption that any of these treatments help and do not harm. I’m fact, we ha…
RT @GermHunterMD: @nikkitheomd But this is under the generous assumption that any of these treatments help and do not harm. I’m fact, we ha…
RT @GermHunterMD: @nikkitheomd But this is under the generous assumption that any of these treatments help and do not harm. I’m fact, we ha…
2/2 given drug. This is not true.” A major problem - Single arm compassionate use studies with no concurrent control group. Not a problem - physicians and HCWs doing their level best to treat very sick patients with no access to clinical trials. https://
@nikkitheomd But this is under the generous assumption that any of these treatments help and do not harm. I’m fact, we have no evidence this is true Below from https://t.co/eO8NPstGvI https://t.co/U8HinMJOH4
RT @CochraneJapan: JAMAよりCOVID19での適応外使用に対する警鐘です。 エボラ感染が拡がった際に適応外使用が色々行われましたが、最終的に効果や安全性が証明されたものはありませんでした。 適応外使用があると、患者が死亡した理由が病気か薬かわかりません。生…
@valerieboyer13 "In reality, the placebo group will always be safer (regarding adverse effects) than the experimental group because patients in the placebo group will receive the established standard of care" https://t.co/QEwlxU9vT8
RT @PauloLotufo: O artigo dele no JAMA é muito bom. Ganhou reportagem no NYT. https://t.co/8sLC95zJFE
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network https://t.co/btb97Hza3c
His family immigrated from Brazil, we are proud of you Dr. Andre Kalil, obrigado !
RT @PauloLotufo: O artigo dele no JAMA é muito bom. Ganhou reportagem no NYT. https://t.co/8sLC95zJFE
RT @PauloLotufo: O artigo dele no JAMA é muito bom. Ganhou reportagem no NYT. https://t.co/8sLC95zJFE https://t.co/7EryFYsLvi
O artigo dele no JAMA é muito bom. Ganhou reportagem no NYT. https://t.co/8sLC95zJFE
RT @GhanaboyPharmd: This is really good!! Thanks @JeffreyFudin for recommending this article.. Sums up everything i have been wrestling wit…
RT @WmHaseltine: An important article highlighting how unproven drugs for Covid-19 like chloroquine, azithromycin, and lopinavir-ritonavir…
RT @smirioglu: Should not be forgotten, especially in times like these. Controlled studies are needed. #COVIDー19 https://t.co/pg5SGaOGQm ht…
Should not be forgotten, especially in times like these. Controlled studies are needed. #COVIDー19 https://t.co/pg5SGaOGQm https://t.co/73iwTBIFqP
@SabrinaSoaresC7 e @CarolNicoloso olhem esse artigo que interessante, fala tudo que discutimos ontem. https://t.co/2eMWVPkTzE
RT @campos: E por fim o artigo do André Kalil da @UNMC_ID na @JAMA_current: https://t.co/ZuYG2u1UPP
RT @PauloLotufo: The survival of critical patients will be determined by the number of nurses per bed and by respiratory therapists. It is…
The survival of critical patients will be determined by the number of nurses per bed and by respiratory therapists. It is crucial! https://t.co/by09ro1Dqv
@MarianneleMag Encore une connasse d'Énarque. L'utilisation de vieux médicaments, en mode panique, "parce qu'il y a urgence" ne nous fait pas avancer. En Allemagne, personne ne parle Hydroxychloroquine. Informez vous avant de publier de la merde. https://t
RT @ymori117: JAMA論説「パンデミックにおけるCOVID-19への薬物適応外使用、未承認薬アクセス制度による使用、無作為比較試験」 https://t.co/u0soye2bWO 「適応外・未承認薬の一般的な解釈は、患者が死亡したら病気の所為だが、生存したら薬物…
RT @WmHaseltine: An important article highlighting how unproven drugs for Covid-19 like chloroquine, azithromycin, and lopinavir-ritonavir…
RT @DrTonyLeachon: Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Phar…
Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network. First do no harm. https://t.co/xJEUmMt5Ee
Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics https://t.co/mvn1TyYrNL
RT @joaqmorera: Que cuando se dice que hay que realizar tratamientos basado en ensayos clínicos es por algo Treating COVID-19—Off-Label and…
RT @GhanaboyPharmd: This is really good!! Thanks @JeffreyFudin for recommending this article.. Sums up everything i have been wrestling wit…
RT @GhanaboyPharmd: This is really good!! Thanks @JeffreyFudin for recommending this article.. Sums up everything i have been wrestling wit…
RT @ymori117: JAMA論説「パンデミックにおけるCOVID-19への薬物適応外使用、未承認薬アクセス制度による使用、無作為比較試験」 https://t.co/u0soye2bWO 「適応外・未承認薬の一般的な解釈は、患者が死亡したら病気の所為だが、生存したら薬物…
RT @ymori117: 新型コロナウイルス、治療薬の話はいろいろ出てるけど、こういうことがあるから、序盤で一点賭けはしないほうが良いと思う。
RT @ymori117: 新型コロナウイルス、治療薬の話はいろいろ出てるけど、こういうことがあるから、序盤で一点賭けはしないほうが良いと思う。 https://t.co/WsYrEE9n3e
RT @ymori117: JAMA論説「パンデミックにおけるCOVID-19への薬物適応外使用、未承認薬アクセス制度による使用、無作為比較試験」 https://t.co/u0soye2bWO 「適応外・未承認薬の一般的な解釈は、患者が死亡したら病気の所為だが、生存したら薬物…